Palma de Mallorca, May 15th 2013. Lipopharma presented yesterday its cancer program with 2OHOA at Biotrinity 2013 and announced the start of the first oncology clinical study with this novel lipid regulator.

After obtaining all required regulatory authorizations in the UK for the clinical study MIN-001-1203, Lipopharma confirmed the activation of the first site in Sutton, Surrey (UK), which will be recruiting participants from today. The other two sites taking part in the first part of the study (in Newcastle and Barcelona) are expected to be also active from the first week of June. The hospital in Zurich will be joining the study in the second phase of the trial, once the dose escalation phase is completed. Up to 50 patients with advanced solid tumors, including malignant glioma, are expected to be enrolled in this clinical trial.

Lipopharma's R&D program in Oncology with 2OHOA was selected to present at BioTrinity 2013, the annual conference created by OBN which features a hand-picked showcase of Europe’s leading emerging life sciences companies, as more than 850 delegates from 30 countries are expected to attend this 2013 edition.


Vicenç Tur, CEO of Lipopharma, presented in the Company Showcase (oncology track) and actively participated in this year's edition of Biotrinity in Newbury (UK) with the objective of pursuing Lipopharma's ongoing contacts with key industry players as well as to explore additional collaborations with investors and new potential industry partners.

Supported by



© 2019 Lipopharma | legal notice Copyright 2011 Lipopharma - Lipopharma announces at Biotrinity 2013 the initiation of the first clinical study in cancer with 2OHOA. All Rights Reserved.
Joomla 1.7 templates by hostgator coupon and learn how to make a website